DOI QR코드

DOI QR Code

Adherence to Recommended Treatments for Early Invasive Breast Cancer: Decisions of Women Attending Surgeons in the Breast Cancer Audit of Australia and New Zealand

  • Roder, David M. (Cancer Australia, Cancer Epidemiology, University of South Australia) ;
  • Silva, Primali De (National Breast Cancer Audit, Breast Surgeons' Society of Australia and New Zealand) ;
  • Zorbas, Helen N. (Cancer Australia) ;
  • Webster, Fleur (Breast Cancer, Cancer Australia) ;
  • Kollias, James (National Breast Cancer Audit, Breast Surgeons' Society of Australia and New Zealand) ;
  • Pyke, Chris M. (University of Queensland) ;
  • Campbell, Ian D. (Waikato Clinical School, Faculty of Medical and Health Sciences, University of Auckland)
  • Published : 2012.04.30

Abstract

Aim: The study aim was to determine the frequency with which women decline clinicians' treatment recommendations and variations in this frequency by age, cancer and service descriptors. Design: The study included 36,775 women diagnosed with early invasive breast cancer in 1998-2005 and attending Australian and New Zealand breast surgeons. Rate ratios for declining treatment were examined by descriptor, using bilateral and multiple logistic regression analyses. Proportional hazards regression was used in exploratory analyses of associations with breast cancer death. Results: 3.4% of women declined a recommended treatment of some type, ranging from 2.6% for women under 40 years to 5.8% for those aged 80 years or more, and with parallel increases by age presenting for declining radiotherapy (p<0.001) and axillary surgery (p=0.006). Multiple regression confirmed that common predictors of declining various treatments included low surgeon case load, treatment outside major city centres, and older age. Histological features suggesting a favourable prognosis were often predictive of declining various treatments, although reverse findings also applied with women with positive nodal status being more likely to decline a mastectomy and those with larger tumours more likely to decline chemotherapy. While survival analyses lacked statistical power due to small numbers, higher risks of breast cancer death were suggested, after adjusting for age and conventional clinical risk factors, (1) for women not receiving breast surgery for unstated reasons (RR=2.29; p<0.001); and (2) although not approaching statistical significance $p{\geq}0.200$), for women declining radiotherapy (RR=1.22), a systemic therapy (RR1.11), and more specifically, chemotherapy (RR=1.41). Conclusions: Women have the right to choose their treatments but reasons for declining recommendations require further study to ensure that choices are well informed and clinical outcomes are optimized.

Keywords

References

  1. Armitage P, Berry G (1987). Statistical methods in medical research. Second edition. Blackwell Scientific Publications, Oxford.
  2. Atkins L, Fallowfield L (2006). Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer, 42, 2271-6. https://doi.org/10.1016/j.ejca.2006.03.004
  3. Australian Institute of Health and Welfare, Cancer Australia & Australasian Association of Cancer Registries (2008). Cancer survival and prevalence in Australia: cancers diagnosed from 1982 to 2004. Cancer series no. 42. Cat. No. CAN 38. AIHW, Canberra.
  4. Breast Cancer Network Australia (2011). Women living in rural and remote regions. BCNA, Melbourne.
  5. Bloom BS, De Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D (2004). Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer, 90, 26-30. https://doi.org/10.1038/sj.bjc.6601439
  6. Cancer Australia (2011). Recommendations for use of hypofractionated radiotherapy for early (operable) breast cancer. CA, Sydney.
  7. Chlebowski RT, Geller ML (2006). Adherence to endocrine therapy for breast cancer. Oncology, 71, 1-9.
  8. Garlinger PM, Abramson JH (1995). Computer programs for epidemiologic analysis. Unicorn Software Development, Inc., Stone Mountain.
  9. Gilligan MA, Neuner J, Sparapani R, Laud PW, Nattinger AB (2007). Surgeon characteristics and variations in treatment for early-stage breast cancer. Arch Surg, 142, 17-22. https://doi.org/10.1001/archsurg.142.1.17
  10. Hebert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschenes L (1999). Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer, 85, 1104-13. https://doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1104::AID-CNCR14>3.0.CO;2-1
  11. Hebert-Croteau N, Brisson J, Latreille J, et al (2004). Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodenegative breast cancer. J Clin Oncol, 22, 3685-93. https://doi.org/10.1200/JCO.2004.07.018
  12. Hershman DL, Shao T, Kushi LH, et al (2011). Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat, 126, 529-37. https://doi.org/10.1007/s10549-010-1132-4
  13. Hoffman M, Levin TT (2005). Doctor, I don't want chemotherapy! J Support Oncol, 3, 97-8.
  14. Land SR, Cronin WM, Wickerham DL, et al (2011). Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project P-1 breast cancer prevention trial. Cancer Prev Res, 4, 1393-400. https://doi.org/10.1158/1940-6207.CAPR-11-0172
  15. Lebeau M, Mathoulin-Pélissier S, Bellera C, et al (2011). Breast cancer care compared with clinical Guidelines: an observational study in France. BMC Public Health, 11, 45.
  16. Li BD, Brown WA, Ampil FL, et al (2000). Patient compliance is critical for equivalent clinical outcomes for breast cancer treated by breast-conservation therapy. Ann Surg, 231, 883-9. https://doi.org/10.1097/00000658-200006000-00013
  17. McCowan C, Shearer J, Donnan PT, et al (2008). Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer, 99, 1763-8. https://doi.org/10.1038/sj.bjc.6604758
  18. (NBOCC) National Breast and Ovarian Cancer Centre (2008). MDIA-A national audit investigating the implementation of multidisciplinary cancer care in Australia. NBOCC publications, Sydney
  19. Partridge AH, LaFountain A, Mayer E (2008). Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol, 26, 556-62. https://doi.org/10.1200/JCO.2007.11.5451
  20. Partridge AH, Avorn J, Wang PS, Winer EP (2002). Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst, 94, 652-61. https://doi.org/10.1093/jnci/94.9.652
  21. Partridge AH, Wang PS, Winer EP, Avorn J (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol, 21, 602-6. https://doi.org/10.1200/JCO.2003.07.071
  22. Roder D, Wang JX, Zorbas H, Kollias J, Maddern G (2010). Survival from breast cancers managed by surgeons participating in the National Breast Cancer Audit of the Royal Australasian College of Surgeons. ANZ J Surg, 11, 776-80.
  23. Roder DM, De Siva P, Zorbas HN, et al (2011). Age effects on survival from early breast cancer in clinical settings in Australia. ANZ J Surg, 11, 776-80.
  24. Ruddy K, Mayer E, Partridge A (2009). Patient adherence and persistence with anticancer treatment. CA Cancer J Clin, 59, 56-66. https://doi.org/10.3322/caac.20004
  25. Ruddy KJ, Partridge AH (2009). Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol, 20, 401-2.
  26. SACR (South Australian Cancer Registry) (2000). Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1999. Incidence and mortality 1999. Openbook Publ., Adelaide
  27. SACR (South Australian Cancer Registry) (2007). Cancer in South Australia 2004 with incidence projections to 2007. Government of South Australia, Adelaide.
  28. Schaapveld M, De Vries EG, Otter R, et al (2005). Guideline adherence for early breast cancer before and after introduction of sentinel node biopsy. Br J Cancer, 93, 520-8. https://doi.org/10.1038/sj.bjc.6602747
  29. StataCorp (2005). Stata Statistical Software. Release 9.2. StataCorp LP, College Station, Texas.
  30. Truong PT, Wong E, Bernstein V, Berthelet E, Kader HA (2004). Adjuvant radiation therapy after breast-conserving surgery in elderly women with early-stage breast cancer: controversy or consensus? Clin Breast Cancer, 4, 407-14. https://doi.org/10.3816/CBC.2004.n.003
  31. Wang J, Boult M, Tyson S, et al (2008a). Trends in surgical treatment of younger patients with breast cancer in Australia and New Zealand. ANZ J Surg, 78, 665-9. https://doi.org/10.1111/j.1445-2197.2008.04613.x
  32. Wang J, Boult M, Roder D, Kollias J, Maddern G (2008b). Commentary: how surgical audits can be used to promote the update of surgical evidence. ANZ J Surg, 78, 437-8. https://doi.org/10.1111/j.1445-2197.2008.04530.x
  33. Weggelaar I, Aben KK, Warlé MC, Strobbe LJ, Van Spronsen DJ (2011). Declined guideline adherence in older breast cancer patients: a population-based study in the Netherlands. Breast J, 17, 239-45. https://doi.org/10.1111/j.1524-4741.2011.01074.x
  34. Wöckel A, Kurzeder C, Geyer V, et al (2010b). Effects of guideline adherence in primary breast cancer - a 5-year multi-center cohort study of 3976 patients. Breast, 19, 120-7. https://doi.org/10.1016/j.breast.2009.12.006
  35. Wöckel A, Varga D, Atassi Z, et al (2010b). Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie, 33, 21-8. https://doi.org/10.1159/000315007

Cited by

  1. Bcl-2 Gene Expression in Human Breast Cancers in Iran vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4209
  2. Breast Cancer at Extreme Ages - a Comparative Analysis in Chile vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1455
  3. Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10 vol.11, pp.3, 2016, https://doi.org/10.1371/journal.pone.0150734